Logotype for Absci Corporation

Absci (ABSI) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Absci Corporation

Q3 2026 earnings summary

12 Nov, 2026

Executive summary

  • ABS-201 HEADLINE is progressing in Phase 1/2a for pattern hair loss; interim 13-week proof-of-concept data are expected in December 2026 and full 26-week data in early 2027.

  • A Phase 2 STORYLINE trial for endometriosis is planned for mid-2027; ABS-202 remains in nonclinical development.

  • Origin-1 generative design paired with lab-in-the-loop validation; the first two programs reached IND or foreign equivalent in ~2 years at ~$15M per program, versus cited industry averages of 4–6 years and >$50M.

Financial highlights

  • Q3 partner program revenue was $0.304M vs. $0.378M YoY; net loss was $33.3M vs. $28.7M.

  • Q3 R&D expense was $23.6M vs. $19.2M, mainly reflecting ABS-201 development; SG&A was $9.0M vs. $8.4M, primarily due to stock-based compensation.

  • 9M revenue was $0.837M vs. $2.150M and net loss was $96.1M vs. $85.6M.

  • 9M R&D expense rose 17% to $65.5M; operating expenses increased 10% to $100.8M, including SG&A of $27.3M and D&A of $8.1M.

  • Q3 diluted loss per share was $0.19 vs. $0.20; 9M diluted loss per share was $0.60 vs. $0.65.

Outlook and guidance

  • Interim 13-week HEADLINE data are expected in December 2026, including all 300 mg participants, most 600 mg participants and potentially an initial look at 1,200 mg; full 26-week data are expected in early 2027.

  • The 26-week results will inform Phase 3 dose selection; the 13-week interim is directional and not intended to change trial conduct.

  • STORYLINE is planned for mid-2027, subject to protocol finalization and regulatory clearance; planned enrollment is ~150 patients across ~10 or more countries.

  • Cash, cash equivalents and marketable securities of $173.7M are projected to fund operating plans into H2 2028.

  • R&D expense is expected to rise as HEADLINE, later-stage PHL trials, STORYLINE, other internal programs and platform investment advance.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Absci